MedStar Georgetown University Hospital Treats 1,000 Prostate Cancer Patients with the CyberKnife® System

March 31, 2016 at 6:00 AM EDT
Patients Benefit from Fewer Treatment Sessions and Minimal Side Effects

SUNNYVALE, Calif., March 31, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that MedStar Georgetown University Hospital in Washington, D.C. treated its 1,000th prostate cancer patient with the leading-edge CyberKnife® System. The System was designed to deliver stereotactic body radiation therapy (SBRT), a treatment process necessitating an extremely high degree of precision. SBRT is a much shorter course of treatment for prostate cancer patients than conventional radiation and is noninvasive (no surgery involved).

Accuray Incorporated

MedStar Georgetown was an early adopter of CyberKnife radiosurgery and continues to pioneer and expand the ways the System is used to treat tumors. In 2012, MedStar Georgetown invested in a second CyberKnife System to meet the growing demand among clinicians and patients interested in the treatment of prostate cancer and other indications. In addition to using CyberKnife radiosurgery to treat prostate cancer, MedStar Georgetown University Hospital is using the System as a treatment method for tumors of the brain, breast, liver, lung, pancreas and spine.

"This patient milestone demonstrates MedStar Georgetown University Hospital's commitment to offering the most advanced technologies available for a broad universe of their patients," said Joshua H. Levine, president and chief executive officer of Accuray. "More and more, our customers are selecting CyberKnife as their system of choice for the treatment of low to intermediate-risk prostate cancer, based on its ability to effectively target and treat this delicate area in five treatment sessions or less, with sub-millimeter precision, and with minimal disruption to patients' daily lives."

The prostate gland can move unpredictably throughout the course of treatment because of normal patient bodily functions, making the ability to track, detect and correct for motion critically important. Unlike any other radiation treatment, the CyberKnife System continually tracks and automatically corrects the beam for movement of the prostate in real-time throughout the entire treatment session. With this automatic motion-tracking and adjustment, the CyberKnife System enhances the doctor's ability to treat with exceptional preservation of healthy tissue. Using the System, physicians can precisely maximize dose in four to five treatment sessions, minimize side effects, and maximize patient comfort during treatment.

Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.

For more information about the CyberKnife® System, visit:

For more information about MedStar Georgetown University Hospital, visit:{}

About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016, and the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Logo -


To view the original version on PR Newswire, visit:

SOURCE Accuray Incorporated

Media: Beth Kaplan, Public Relations Director, Accuray, +1 (408) 789-4426,; Danielle Sullivan, MSLGROUP, +1 (781) 684-6680,